CELLECTIS - ADR (CLLS:NASDAQ)
$3.59 0.09 (2.5714%)
Analysed CELLECTIS - ADR (CLLS:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
10-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
09-04-2026
yahoo.com
Monthly information on share capital and company voting rights
07-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
07-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
06-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday Trading
01-04-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
31-03-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
30-03-2026
yahoo.com
Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ...
20-03-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week
20-03-2026
yahoo.com
What is the current price of CELLECTIS - ADR (CLLS:NASDAQ)?
The current price of CELLECTIS - ADR (CLLS:NASDAQ) is $3.59.
CELLECTIS - ADR (CLLS:NASDAQ) absolute price change since previous trading day?
The absolute price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is $0.09.
CELLECTIS - ADR (CLLS:NASDAQ) percentage price change since previous trading day?
The percentage price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is 2.5714%.
What is the most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ) is 46 out of 100.
What is the most recent average sentiment for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent sentiment for CELLECTIS - ADR (CLLS:NASDAQ) is .
SEC-8K** Filing Available For CELLECTIS - ADR (CLLS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.